Hong Kong
· Delayed Price · Currency is HKD Viva Biotech Holdings Statistics
Total Valuation
Viva Biotech Holdings has a market cap or net worth of HKD 1.29 billion. The enterprise value is 1.84 billion.
| Market Cap | 1.29B |
| Enterprise Value | 1.84B |
Important Dates
The next estimated earnings date is Friday, November 29, 2024.
| Earnings Date | Nov 29, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Viva Biotech Holdings has 2.14 billion shares outstanding. The number of shares has increased by 7.22% in one year.
| Shares Outstanding | 2.14B |
| Shares Change (YoY) | +7.22% |
| Shares Change (QoQ) | +0.06% |
| Owned by Insiders (%) | 39.59% |
| Owned by Institutions (%) | 1.25% |
| Float | 1.04B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.57 |
| PB Ratio | 0.32 |
| P/FCF Ratio | 309.59 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 4.40, with an EV/FCF ratio of 443.73.
| EV / Earnings | -5,390.38 |
| EV / Sales | 0.86 |
| EV / EBITDA | 4.40 |
| EV / EBIT | 9.28 |
| EV / FCF | 443.73 |
Financial Position
The company has a current ratio of 1.65, with a Debt / Equity ratio of 40.53.
| Current Ratio | 1.65 |
| Quick Ratio | 1.27 |
| Debt / Equity | 40.53 |
| Debt / EBITDA | 3.96 |
| Debt / FCF | 398.92 |
| Interest Coverage | 1.54 |
Financial Efficiency
Return on equity (ROE) is 0.83% and return on invested capital (ROIC) is 1.94%.
| Return on Equity (ROE) | 0.83% |
| Return on Assets (ROA) | 1.51% |
| Return on Capital (ROIC) | 1.94% |
| Revenue Per Employee | 1.05M |
| Profits Per Employee | -167 |
| Employee Count | 2,077 |
| Asset Turnover | 0.26 |
| Inventory Turnover | 5.26 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -53.49% in the last 52 weeks. The beta is 1.23, so Viva Biotech Holdings's price volatility has been higher than the market average.
| Beta (5Y) | 1.23 |
| 52-Week Price Change | -53.49% |
| 50-Day Moving Average | 0.52 |
| 200-Day Moving Average | 0.65 |
| Relative Strength Index (RSI) | 64.14 |
| Average Volume (20 Days) | 2,113,300 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Viva Biotech Holdings had revenue of HKD 2.14 billion and -341,690 in losses. Loss per share was -0.10.
| Revenue | 2.14B |
| Gross Profit | 721.64M |
| Operating Income | 198.43M |
| Pretax Income | 99.73M |
| Net Income | -341,690 |
| EBITDA | 406.53M |
| EBIT | 198.43M |
| Loss Per Share | -0.10 |
Balance Sheet
The company has 1.11 billion in cash and 1.66 billion in debt, giving a net cash position of -542.81 million or -0.25 per share.
| Cash & Cash Equivalents | 1.11B |
| Total Debt | 1.66B |
| Net Cash | -542.81M |
| Net Cash Per Share | -0.25 |
| Equity (Book Value) | 4.08B |
| Book Value Per Share | 1.90 |
| Working Capital | 819.85M |
Cash Flow
In the last 12 months, operating cash flow was 234.55 million and capital expenditures -230.40 million, giving a free cash flow of 4.15 million.
| Operating Cash Flow | 234.55M |
| Capital Expenditures | -230.40M |
| Free Cash Flow | 4.15M |
| FCF Per Share | 0.00 |
Margins
Gross margin is 33.66%, with operating and profit margins of 9.26% and -0.02%.
| Gross Margin | 33.66% |
| Operating Margin | 9.26% |
| Pretax Margin | 4.65% |
| Profit Margin | -0.02% |
| EBITDA Margin | 18.96% |
| EBIT Margin | 9.26% |
| FCF Margin | 0.19% |
Dividends & Yields
Viva Biotech Holdings does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.22% |
| Shareholder Yield | -7.22% |
| Earnings Yield | -16.16% |
| FCF Yield | 0.32% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |